Related references
Note: Only part of the references are listed.How will B-cell-receptor-targeted therapies change future CLL therapy?
Jeffrey A. Jones et al.
BLOOD (2014)
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
Jennifer A. Woyach et al.
BLOOD (2014)
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Peter Dreger et al.
BLOOD (2014)
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion
Paolo Strati et al.
HAEMATOLOGICA (2014)
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
Jan A. Burger et al.
LANCET ONCOLOGY (2014)
Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center
D. M. Stephens et al.
LEUKEMIA (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients
Annika Dufour et al.
BLOOD (2013)
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau et al.
CELL (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
B cell receptor signaling in chronic lymphocytic leukemia
Jan A. Burger et al.
TRENDS IN IMMUNOLOGY (2013)
Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns
Anna Schuh et al.
BLOOD (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial
Andrew R. Pettitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia
T. Elter et al.
LEUKEMIA (2012)
Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia
Giles Best et al.
LEUKEMIA & LYMPHOMA (2012)
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia
Sameer A. Parikh et al.
BLOOD (2011)
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
Xavier C. Badoux et al.
BLOOD (2011)
Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial
David Gonzalez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories
M. Fiegl et al.
ANNALS OF ONCOLOGY (2010)
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
Peter Dreger et al.
BLOOD (2010)
Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation
David Oscier et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
Thorsten Zenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia
Stephan Stilgenbauer et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience
Pau Abrisqueta et al.
BLOOD (2009)
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
Thorsten Zenz et al.
BLOOD (2009)
Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia
Francesc Bosch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
Stephan Stilgenbauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease
O. G. Best et al.
LEUKEMIA (2009)
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study
A. Cortelezzi et al.
LEUKEMIA (2009)
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy
Ellen J. Schlette et al.
LEUKEMIA & LYMPHOMA (2009)
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Constantine S. Tam et al.
BLOOD (2008)
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia:: results from a detailed genetic characterization with long-term follow-up
Thorsten Zenz et al.
BLOOD (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis
Johannes Schetelig et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D. Catovsky et al.
LANCET (2007)
Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia
Issa F. Khouri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Programmed anuclear cell death delimits platelet life span
Kylie D. Mason et al.
CELL (2007)
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features
Deborah A. Bowen et al.
LEUKEMIA & LYMPHOMA (2007)
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy
Constantine S. Tam et al.
LEUKEMIA & LYMPHOMA (2007)
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
P. Dreger et al.
LEUKEMIA (2007)
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia
Tait D. Shanafelt et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects
A. R. Pettitt et al.
LEUKEMIA (2006)
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
N Lamanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia
JG Gribben et al.
BLOOD (2005)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis
P Dreger et al.
LEUKEMIA (2005)
Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia
C Moreno et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
G Lozanski et al.
BLOOD (2004)
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response
A Rosenwald et al.
BLOOD (2004)
Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status:: implications of minimal residual disease measurement with quantitative PCR
M Ritgen et al.
BLOOD (2004)
Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning
P Dreger et al.
LEUKEMIA (2003)
High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities
PD Thornton et al.
ANNALS OF HEMATOLOGY (2003)
Nonmyeloablative transplantation with or without alemtuzumab:: comparison between 2 prospective studies in patients with lymphoproliferative disorders
JA Pérez-Simón et al.
BLOOD (2002)
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine
KR Rai et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy
S Stilgenbauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
MJ Keating et al.
BLOOD (2002)
Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation
IF Khouri et al.
CYTOTHERAPY (2002)
Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status
J Esteve et al.
LEUKEMIA (2001)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
